Biodexa Pharmaceuticals PLC
BDRX1.240USD
-0.060-4.62%
終値 02/06, 16:00（ET）15分遅れの株価
7.68B時価総額
7.11直近12ヶ月PER
詳細情報 Biodexa Pharmaceuticals PLC 企業名
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLCの企業情報
企業コードBDRX
会社名Biodexa Pharmaceuticals PLC
上場日Dec 08, 2014
最高経営責任者「CEO」Stamp (Stephen A)
従業員数- -
証券種類Depository Receipt
決算期末Dec 08
本社所在地1 Caspian Point
都市ABINGDON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United Kingdom
郵便番号CF10 4DQ
電話番号4401235888300
ウェブサイトhttps://www.biodexapharma.com/
企業コードBDRX
上場日Dec 08, 2014
最高経営責任者「CEO」Stamp (Stephen A)
Biodexa Pharmaceuticals PLCの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
Belgium
381.00K
100.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Mon, Feb 2
更新時刻: Mon, Feb 2
株主統計
種類
株主統計
株主統計
比率
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
UBS Financial Services, Inc.
0.31%
GAMMA Investing LLC
0.29%
District 2 Capital LP
0.07%
他の
96.24%
株主統計
株主統計
比率
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
UBS Financial Services, Inc.
0.31%
GAMMA Investing LLC
0.29%
District 2 Capital LP
0.07%
他の
96.24%
種類
株主統計
比率
Investment Advisor/Hedge Fund
2.99%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.31%
Hedge Fund
0.07%
Bank and Trust
0.03%
Research Firm
0.02%
他の
95.63%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
25
26.99K
4.95%
--
2025Q3
27
27.63K
4.95%
+6.43K
2025Q2
30
21.20K
5.92%
-17.70K
2025Q1
32
21.37K
16.41%
+10.40K
2024Q4
31
19.96K
16.99%
+9.20K
2024Q3
33
10.76K
4.86%
+5.02K
2024Q2
29
4.42K
2.68%
+1.32K
2024Q1
25
3.10K
2.07%
+2.75K
2023Q4
26
3.28K
0.82%
+3.22K
2023Q3
18
57.00
107.67%
+15.00
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
GAMMA Investing LLC
1.78K
0.29%
+425.00
+31.43%
Dec 31, 2025
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
UBS Switzerland AG
6.92K
1.12%
+6.73K
+3379.90%
Sep 30, 2025
SBI Securities Co., Ltd.
115.00
0.02%
-452.00
-79.72%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
5.00
0%
-2.00
-28.57%
Sep 30, 2025
Contravisory Investment Management, Inc.
--
0%
-4.00
-100.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
--
0%
-8.00
-100.00%
Apr 30, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
日付
配当落ち日
種類
比率
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
詳細を見る
